Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Plus Multi-Kinase Inhibitor in Advanced Hepatocellular Carcinoma
NCT05168163Phase 2Recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Academic and Community Cancer Research United. Primary endpoints: Overall Survival at 3 years and Progression-Free Survival at 2 years. Started May 2022; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05168163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168163.